Proton Pump Inhibitors: Helpful or Hurtful?

Heartburn medication is the most ordinary drug in the American medicine cabinet. Roughly a dozen proton pump inhibitors are sold here, several without a prescription, and millions of people take one for years because nobody ever told them to stop. A smaller number end up in a nephrologist’s office with kidney function that has quietly deteriorated, and the question they arrive with is whether the pill they bought at the grocery store had anything to do with it. Boesen Law handles product liability claims involving prescription and over-the-counter drugs, and this is one of the calls we take most often.

The earlier version of this article was written in 2018 and listed risks that have since sorted themselves into two categories that behave nothing alike: the ones the FDA put in the drug’s warnings, and the ones that stayed in observational research and never made it there. Getting that distinction right matters more than any list, because a warned-about risk and a debated one behave completely differently in a courtroom. What follows separates them, then covers what Colorado law actually requires of a claim.

What These Drugs Do and Why People Stay On Them for Years

Proton pump inhibitors shut down the enzyme that pumps acid into the stomach. They treat gastroesophageal reflux disease, erosive esophagitis, ulcers, and Zollinger-Ellison syndrome, and they do it well enough that most patients notice within days.

The family includes esomeprazole (Nexium), omeprazole (Prilosec and Zegerid), lansoprazole (Prevacid), pantoprazole (Protonix), dexlansoprazole (Dexilant), and rabeprazole (AcipHex). Several are sold over the counter in fourteen-day courses meant to be repeated no more than three times a year.

That last detail is where the problem starts. The labeled short-course regimen and real-world use have almost nothing to do with each other. People refill an over-the-counter package indefinitely, or stay on a prescription that was written years ago for a condition that resolved, because stopping brings the reflux back and nobody scheduled a conversation about tapering. Nearly every risk described below is tied to duration.

For answers to your questions, call:
(303) 999-9999

What the FDA-Approved Warnings Actually Say

The most reliable source on any drug is its current label, because those warnings survived FDA review rather than a press cycle. The FDA-approved prescribing information for Nexium, which reflects proton pump inhibitor class labeling, carries these warnings and precautions.

Two things stand out in that list for anyone thinking about a claim. The kidney warning is not limited to long-term users, since the label says nephritis may occur at any point during therapy. And almost every other warning is explicitly duration-dependent, which means the prescribing history is the evidence.

The Kidney Injury at the Center of the Lawsuits

Acute tubulointerstitial nephritis is inflammation in the tissue between the kidney’s tubules. When a drug triggers it, the immune response damages the filtering apparatus.

What makes it dangerous is how little it announces. Classic drug-allergy signs such as fever, rash, and joint pain are often absent, which is exactly what the label warns clinicians about. Patients feel tired, off their food, mildly nauseated. Those symptoms get attributed to age, to another medication, to a virus. By the time creatinine is checked and comes back elevated, the inflammation may have been running for months.

Some patients recover fully once the drug stops. Others do not, and the residual scarring leaves chronic kidney disease that continues to progress, in the worst cases to dialysis or a transplant list. The difference between the two outcomes usually comes down to how quickly the drug was identified and stopped, which is why prescribing records and the sequence of laboratory results are the backbone of a claim rather than a supporting document.

Kidney failure of that severity reshapes a working life as thoroughly as any catastrophic injury, and clients often pursue a Social Security disability claim on a parallel track.

Two Risks the Older Version of This Post Got Wrong

The 2018 article listed dementia and pneumonia alongside the labeled risks. That was the state of the coverage at the time, and it has not held up.

Neither dementia nor pneumonia appears in the FDA-approved warnings for these drugs. Neither does chronic kidney disease as a standalone warning, even though acute tubulointerstitial nephritis does. Observational studies have reported associations for all three, and those studies generated a great deal of press, but an association reported in a database study is not the same as an established causal risk, and the FDA has not required either warning in the years since.

The distinction is not academic. A failure-to-warn claim is built on what the manufacturer knew and what the label said. A risk that sits in the approved warnings gives a plaintiff a documented, company-acknowledged hazard to work from. A risk that never made it into labeling has to be proven from the underlying science, against a manufacturer that will point out the FDA declined to require it. Any article that flattens those two categories into one bullet list is doing readers a disservice.

Where the Proton Pump Inhibitor Litigation Stands

Unlike most drug litigations from this era, this one is genuinely still running, and the federal numbers are public.

The federal cases are consolidated as MDL 2789, In re Proton-Pump Inhibitor Products Liability Litigation (No. II), before Judge Claire C. Cecchi in the District of New Jersey. The Judicial Panel on Multidistrict Litigation’s pending MDL report dated July 1, 2026 shows 11,321 actions pending out of 18,706 filed over the life of the docket. That places it among the five largest active product liability proceedings in the federal system.

Those figures describe a live docket. They do not describe whether any particular person still has a claim, which is a question of Colorado law and individual dates rather than of national caseload. Anyone who reads a caseload number as an invitation is reading it wrong.

How Colorado Law Treats a Drug Injury Claim

The framework is product liability, and the timing rules are stricter than most people expect.

A claim against the manufacturer or seller of a drug for personal injury caused by its manufacture, formula, labeling, or a failure to warn falls under C.R.S. § 13-80-106, which opens a two-year window running from the moment the claim for relief arises, no matter which legal theory is pleaded. Strict liability and inadequate-warning theories carry the identical window under § 13-80-102. There is no longer alternative anywhere in the statute.

Accrual is where these cases are won or lost. C.R.S. § 13-80-108(1) starts that clock only once an injured person knows, or with reasonable diligence would know, two separate things: that they were hurt, and what produced the harm. A patient told in 2024 that their kidney function had declined, and told nothing about why, is in a different position from one whose nephrologist wrote “likely PPI-induced” in the chart that same week. Establishing which of those happened, and when, is the first work in the file, and Colorado’s personal injury filing deadlines follow the same logic across claim types.

Colorado also gives drug manufacturers a presumption to work with. C.R.S. § 13-21-403(1) provides that a product is rebuttably presumed not defective, and its maker not negligent, if it complied with an applicable federal code, standard, or regulation at the time of sale. Subsection (2) runs the presumption the other way where a product did not comply. In a pharmaceutical case that turns the argument toward what the company told the FDA and when, and toward whether the labeling matched what the company’s own safety data showed. Boesen Law approaches these files as mass tort matters for that reason, because the proof lives in the manufacturer’s regulatory history rather than in any single medical record.

An Attorney’s View on Drug Injury Claims

Stephen A. Justino, a personal injury attorney with 32 years of legal experience who is recognized in Colorado for handling negligence claims against the United States under the Federal Tort Claims Act, notes:

“Drug cases turn on the paper trail, and the paper trail belongs to two parties who are not the client. One is the pharmacy, which can produce a dispensing history going back years and settle the duration question in an afternoon. The other is the manufacturer, whose adverse event reporting and regulatory correspondence show what it knew before the warning was written. Clients tend to arrive focused on how sick they are, which makes sense and is not the part I worry about. What I want in the first week is the fill history, the creatinine values in order with dates, and the note where somebody first wrote down a suspicion. If those three things line up, there is a case. If they do not, no amount of injury makes one.”

The damages picture in a serious kidney case runs well past medical bills, into dialysis logistics, transplant candidacy, lost earning capacity, and the daily cost of a schedule built around treatment. Colorado allows recovery across the full range of damages in a personal injury lawsuit, and health plan subrogation interests usually have to be resolved as part of any settlement.

What Cases Like Yours Have Recovered

Boesen Law recovered $14,800,000 in a medical negligence matter where negligent doctors caused lifelong permanent disability to a client during birth and significantly injured the mother as well, in a joint settlement covering both. The firm also recovered $500,000 for a client whose deep peroneal nerve was damaged by an incorrectly placed nerve block during surgery to remove a leg tumor, leaving the client largely wheelchair-bound. Both involved proving that a permanent impairment traced back to a specific medical decision, which is the same proof problem a drug injury claim presents. Our case results reflect what that work produces.

Contact a Colorado Drug Injury Lawyer at Boesen Law

If you took a proton pump inhibitor for an extended period and have since been told your kidney function has declined, the most useful thing you can do before calling anyone is request your pharmacy dispensing history and your laboratory results with dates attached. Those two documents answer more questions in five minutes than an hour of conversation will.

Your recovery is our priority, Boesen Law has recovered hundreds of millions of dollars for clients across Colorado, someone answers our phone at any hour, and you owe no attorney fee unless we recover money for you. Contact Boesen Law to arrange a free, in-person consultation, and bring the pill bottles if you still have them.

FAQs About Proton Pump Inhibitor Kidney Injury Claims

Which kidney condition are the proton pump inhibitor lawsuits actually about?

Acute tubulointerstitial nephritis is the injury named in the FDA-approved warnings, and it is the anchor of the litigation. The label states that it has been observed in patients taking these drugs and may occur at any point during therapy, and it warns clinicians that patients may present without the fever, rash, or joint pain that usually flags a drug reaction. Claims involving chronic kidney disease or end-stage renal failure are generally built as the downstream consequence of nephritis that went unrecognized, rather than as a separately warned-about risk, which is a meaningful difference in how the case has to be proven.

Do over-the-counter versions carry the same risks as prescription ones?

The active ingredient is the same, and so is the class labeling. What differs is the intended regimen. Over-the-counter packages are labeled for a fourteen-day course repeated no more than three times a year, while the risks that matter most here are tied to months or years of continuous use. Patients who bought the drug off a shelf for four years generally never had a conversation with a prescriber about duration, and their dispensing record may be scattered across several pharmacies and retailers. Reconstructing that history is one of the first tasks in an over-the-counter case.

How long do I have to bring a claim in Colorado, and when does the clock start?

Two years, and the start date is the contested part. An action against a drug manufacturer or seller has to be filed inside two years of the date the claim for relief arises under C.R.S. § 13-80-106, whatever legal theory is pleaded. C.R.S. § 13-80-108(1) ties that arising date to the point at which a patient knew, or with reasonable diligence would have known, both the injury and what produced it. Being told your creatinine is high is not automatically the same day you learned a medication caused it. The chart notes usually settle the question, which is why they get pulled first.

Should I stop taking my proton pump inhibitor because of this?

That is a decision for your physician, not for a law firm or an article. These drugs treat conditions that can cause real harm if left untreated, including erosive esophagitis and bleeding ulcers, and stopping abruptly can produce rebound acid symptoms. What is worth raising at your next appointment is whether you still need it, whether the dose can come down, and whether your kidney function and magnesium have been checked recently. The FDA label itself directs patients toward the lowest dose and shortest duration appropriate to the condition being treated.

What records make the difference in a case like this?

Four things, in this order. The pharmacy dispensing history, which establishes what you took and for how long. Serial creatinine and glomerular filtration rate results with dates, which show when kidney function began to decline. Any biopsy report, since nephritis confirmed on biopsy is far stronger evidence than nephritis inferred. And the clinical note where a physician first connected the two, because that note usually sets the accrual date the defense will argue about. Gathering them early costs nothing and settles most of the threshold questions.

Call (303) 999-9999 or complete a Free Case Evaluation form